Vadadustat - Akebia Therapeutics

Drug Profile

Vadadustat - Akebia Therapeutics

Alternative Names: AKB-6548; MT 6548; PG-1016548

Latest Information Update: 07 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Procter & Gamble
  • Developer Akebia Therapeutics; Mitsubishi Tanabe Pharma Corporation
  • Class Antianaemics; Chlorophenols; Pyridines; Small molecules
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Anaemia

Most Recent Events

  • 11 Apr 2018 Akebia Therapeutics terminates the FO2RWARD phase II trial in Anaemia in USA, to revise study design (NCT03140722)
  • 14 Mar 2018 Phase-III clinical trials in Anaemia in Japan (PO) (NCT03461146)
  • 12 Mar 2018 Akebia Therapeutics has issued or pending patents for processes for manufacturing vadadustat, dosing regimens, formulations, and various other aspects relating to the treatment of anaemia using vadadustat in countries worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top